Published in Cochrane Database Syst Rev on August 15, 2012
UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut (2015) 1.20
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis. World J Hepatol (2014) 0.86
Endoscopic treatment of esophageal varices in patients with liver cirrhosis. World J Gastroenterol (2014) 0.84
Comorbidity in cirrhosis. World J Gastroenterol (2014) 0.80
The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. Clin Mol Hepatol (2014) 0.80
Knowledge about non-invasive diagnostic tests for varices in liver cirrhosis: A questionnaire survey to the Gastroenterology Branch of the Liaoning Medical Association, China. Gastroenterol Rep (Oxf) (2015) 0.79
Management of variceal hemorrhage: current concepts. Arq Bras Cir Dig (2014) 0.79
Factors impacting physicians' decisions to prevent variceal hemorrhage. BMC Gastroenterol (2015) 0.78
Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding. N Am J Med Sci (2013) 0.78
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Role of endoscopy in management of gastrointestinal complications of portal hypertension. World J Gastrointest Endosc (2015) 0.75
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Quality of Care in the Cirrhotic Patient. Clin Transl Gastroenterol (2016) 0.75
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J (2015) 0.75
Fighting Hepatitis B in North Korea: Feasibility of a Bi-modal Prevention Strategy. J Korean Med Sci (2015) 0.75
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol (2016) 0.75
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75
Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology (2010) 1.77
Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. Liver Int (2009) 1.50
Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev (2012) 0.99
Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol (2011) 0.93
Characteristics of randomised trials on diseases in the digestive system registered in ClinicalTrials.gov: a retrospective analysis. BMJ Open (2011) 0.91
Pathophysiological aspects of pulmonary complications of cirrhosis. Scand J Gastroenterol (2007) 0.87
High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. Eur J Gastroenterol Hepatol (2012) 0.87
Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. Liver Int (2012) 0.85
The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review. Dis Colon Rectum (2013) 0.84
Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open (2013) 0.84
Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol (2015) 0.84
Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open (2012) 0.83
Cameron lesions: an often overlooked cause of iron deficiency anaemia in patients with large hiatal hernias. BMJ Case Rep (2010) 0.83
The heart and the liver. Expert Rev Gastroenterol Hepatol (2009) 0.81
Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res (2012) 0.81
Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther (2013) 0.80
Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. Scand J Gastroenterol (2013) 0.79
Adherence to guidelines in bleeding oesophageal varices and effects on outcome: comparison between a specialized unit and a community hospital. Eur J Gastroenterol Hepatol (2010) 0.79
Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol (2013) 0.79
Hyponatraemia during terlipressin therapy. Gut (2010) 0.79
The recent reduction in mortality from bleeding oesophageal varices is primarily observed from Days 1 to 5. Liver Int (2009) 0.78
Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses (2013) 0.78
Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver Int (2014) 0.78
Hyponatremia in patients treated with terlipressin: mechanisms and implications for clinical practice. Hepatology (2011) 0.78
Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. AIDS (2014) 0.77
Betablockers induce cardiac chronotropic incompetence. J Hepatol (2012) 0.77
Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. Scand J Gastroenterol (2015) 0.76
Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. Liver Int (2014) 0.76
Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. Am J Physiol Gastrointest Liver Physiol (2010) 0.76
Effects of treatment with β-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis. Eur J Gastroenterol Hepatol (2011) 0.76
Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites? Hepatology (2010) 0.75
Terlipressin vs. octreotide in bleeding esophageal varices. Am J Gastroenterol (2009) 0.75
A rare cause of severe hepatomegaly with an improving outcome. BMJ Case Rep (2014) 0.75
Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis. Am J Gastroenterol (2010) 0.75
Cutaneous Porphyrias: Causes, Symptoms, Treatments and the Danish Incidence 1989-2013. Acta Derm Venereol (2016) 0.75
Nutrition impact symptoms, handgrip strength and nutritional risk in hospitalized patients with gastroenterological and liver diseases. Scand J Gastroenterol (2015) 0.75
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev (2017) 0.75
[Severe hyponatraemia to terlipressin treatment]. Ugeskr Laeger (2013) 0.75
[In Process Citation]. Ugeskr Laeger (2014) 0.75
[Coffee can be beneficial for patients with liver diseases]. Ugeskr Laeger (2014) 0.75